En Es
Categories

Industry News

Seegene Develops World’s First Multiplex MDx Assays with AI System

By Labmedica International staff writers
09 Jan 2018

Image: Seegene has developed the world’s first molecular diagnostics assays using an artificial intelligence-based automated assay development system (Photo courtesy of Seegene).Seegene Inc. (Seoul, South Korea), a developer of multiplex PCR technologies, successfully developed molecular diagnostics (MDx) assays in just four days using an artificial intelligence- (AI) based automated assay development system. These assays are high multiplex real-time PCR reagents developed completely by AI and are meant for the simultaneous detection of eight different DNA targets for each of meningitis and sexually transmitted infections.

The Seegene Digitalized Development System (SG-DDS) automates real-time PCR assay development by utilizing big data of causative agents for diseases, Seegene's novel algorithms, and in silico oligonucleotide design with virtual experiments. This significantly reduces the time and labor required for R&D and simplifies the complicated real time PCR assay development processes, thereby allowing even non-professionals to easily develop multiplex MDx assays according to their requirement.

"The performance (sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed," said a spokesperson from Seegene. "Only four days were sufficient by the AI system to successfully develop two 8-plex assays, while more than a year was required by a team of experienced professionals."

"We have already witnessed AI surpassing human intelligence in developing medical devices. Therefore, all molecular diagnostic assays will be developed by AI instead of professional researchers," added Dr. Jong-Yoon Chun, CEO and Founder of Seegene. "SG-DDS is now the most economical solution to MDx assay development as it saves time and labor, and will ultimately drive down the cost of molecular diagnostic tests, one of the biggest obstacles in MDx market. SG-DDS will lead to standardization of MDx system and promote tailor-made medical treatment."



E-mail Print
FaceBook Twitter Google+ Linked in

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology. The company’s products detect multi-pathogens with high sensitivity, specificity and reproducibility, resulting in saving of time, labor and cost.
More info

More articles about Seegene

19 Apr 2018
Seegene Unveils Combination Test at ECCMID 2018
Seegene Inc., a developer of multiplex PCR technologies, introduced a combination test at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2018) held in Madrid, Spain, from April 21 to 24, 2018. The combination test is a high-efficiency solution that diagnoses various causes of diseases with multiplex molecular diagnosis assays. Seegene also showcased its molecular diagnostic system SGSTAR (Seegene Sameday Test and Report), which allows order-to-report on the same day and enables the running of the combination test.
Read More
28 Sep 2017
Seegene Partners with Hamilton to Develop Random Access System
Seegene, a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx), has signed a Memorandum of Understanding (MoU) with Hamilton Company, which designs and manufactures precision measurement devices, automated liquid handling workstations, and sample management systems, to develop the Seegene Random Access System.
Read More
29 May 2017
Seegene Collaborates with Thermo to Enter US Market
Seegene Inc., a developer of multiplex molecular diagnostics technologies and assays, has entered into a collaboration with Thermo Fisher Scientific, in which Seegene will file for U.S. Food and Drug Administration (FDA) clearance of its Allplex diagnostic assay portfolio at the same time that Thermo Fisher files for FDA clearance to run Seegene's assays on Thermo Fisher's QuantStudio 5 Real-Time PCR System (PCR System).
Read More

Additional news

19 Jul 2018
Global Ambulatory Surgical Centers Market to Reach USD 97 Billion by 2024
The global ambulatory surgical centers (ASCs) market is estimated to have been valued at USD 77.1 billion in 2017 and is expected to grow at a CAGR of 3.5% to reach USD 97.3 billion by 2024, driven mainly by the growing number of surgeries performed in ASCs and increasing accidental cases. Some key advantages of using ASCs such as the personal attention received by patients and lack of exposure to a wide range of infections will also aid the market growth over the coming years.
Read More
19 Jul 2018
Global Critical Care Diagnostics Market to Reach USD 1.3 Billion by 2024
The global critical care diagnostics (CCD) market is estimated to have been valued at USD 837.6 million in 2015 and is expected to reach USD 1.3 billion by 2024, driven by increasing awareness among physicians, patients’ requirements for cost-efficient, rapid, and accurate diagnostic tests, and technological advancements. However, the high costs of these tests and scarcity of skilled labor for handling new platforms pose a challenge to the market growth.
Read More
16 Jul 2018
Guerbet and IBM Watson Health to Jointly Develop AI Software
Guerbet, which specializes in contrast agents and solutions for diagnostic and interventional medical imaging, has signed an agreement with IBM Watson Health to jointly develop an artificial intelligence (AI) software solution for supporting liver cancer diagnostics and care.
Read More
12 Jul 2018
Global Surgical Tables and Lights Market to Surpass USD 1.8 Billion by 2026
The global surgical tables and lights market was valued at more than USD 1.30 billion in 2017 and is projected to grow at a CAGR of over 3.0% over 2018 to 2026 to surpass USD 1.80 billion by 2026. The demand for surgical tables and lights during the forecast period is likely to be driven by developing health care infrastructure in the emerging countries and the introduction of technologically-advanced surgical tables and lights by the market players. However, constant evolution in the surgical tables and lights segment, with the introduction of new features and designs has led to high prices of these products, thereby acting as a major restraint to the market growth.
Read More
12 Jul 2018
Global Endoscopy Ultrasound Market to Reach USD 1 Billion by 2026
The global endoscopy ultrasound market was valued at approximately USD 650 million in 2017 and is expected to grow at a CAGR of over 5.0% from 2018 to 2026 to reach USD 1.0 billion by 2026. The market growth is being driven by an increase in the incidence of gastrointestinal (GI) cancers, rise in endoscopy ultrasound applications as a diagnostic and therapeutic tool for GI cancers and other pancreatic conditions, and growing number of new and advanced products introduced in the global market. However, the lack of training and educational programs conducted and implemented globally is leading to a shortage of adequately trained professionals who are adept at performing endoscopy ultrasound techniques. This has resulted in a gap between demand for and supply of endoscopy ultrasound procedures globally, thereby restraining market growth.
Read More
10 Jul 2018
Global Contrast Injectors Market Driven by Increasing Chronic Diseases
The global contrast injectors market is expected to grow at a CAGR of 5.07% over the forecast period 2018-2022, driven primarily by increasing chronic diseases. In recent years, there has been a significant increase in the demand for medical devices such as contrast injectors for treating such chronic illness arising from the growing incidence of cardiovascular diseases as a result of obesity and increase in blood pressure. These are the latest findings of Research and Markets, a global market research company.
Read More
05 Jul 2018
EKF Diagnostics Releases Educational Guide to Good Capillary Blood Sampling
Global in vitro diagnostics company EKF Diagnostics has published an educational guide, which provides a quick overview of capillary blood sampling best practice. The new guide aims to help health care professionals understand the common causes of pre-analytical errors and reduce their impact on hemoglobin results.
Read More
05 Jul 2018
New AI Software Could Reduce Patient Time at Hospitals
Canadian researchers have developed an innovative "virtual assistant" — an Artificial Intelligence (AI) health monitoring solution for an existing secure health monitoring platform — to help patients, their healthcare providers, and caregivers remotely manage chronic conditions such as diabetes, hypertension, and heart failure. The virtual assistant, developed by the National Research Council of Canada and Greybox Solutions Inc. aims to reduce the considerable time spent in hospitals and healthcare centers by millions of Canadians affected by chronic illnesses.
Read More
04 Jul 2018
Researchers Use AI to Improve Mammogram Interpretation
A team of researchers at the Department of Energy’s Oak Ridge National Laboratory successfully used artificial intelligence to improve understanding of the cognitive processes involved in image interpretation. Their work, which was published in the Journal of Medical Imaging, will help reduce errors in the analyses of diagnostic images by health professionals and has the potential to improve health outcomes for women affected by breast cancer.
Read More
Copyright © 2000-2018 TradeMed.com. All rights reserved. | Terms And Conditions